Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 349 to 352 of 352 entries
Sorted by: Best Match Show Resources per page
Solid-state nanopore analysis of human genomic DNA shows unaltered global 5-hydroxymethylcytosine content associated with early-stage breast cancer.

Nanomedicine : nanotechnology, biology, and medicine

Zahid OK, Rivas F, Wang F, Sethi K, Reiss K, Bearden S, Hall AR.
PMID: 33905828
Nanomedicine. 2021 Jul;35:102407. doi: 10.1016/j.nano.2021.102407. Epub 2021 Apr 24.

5-Hydroxymethylcytosine (5hmC), the first oxidized form of the well-known epigenetic modification 5-methylcytosine, is an independent regulator of gene expression and therefore a potential marker for disease. Here, we report on methods developed for a selective solid-state nanopore assay that...

Cite
Zahid OK, Rivas F, Wang F, et al. Solid-state nanopore analysis of human genomic DNA shows unaltered global 5-hydroxymethylcytosine content associated with early-stage breast cancer. Nanomedicine. 2021;35:102407doi: 10.1016/j.nano.2021.102407.
Zahid, O. K., Rivas, F., Wang, F., Sethi, K., Reiss, K., Bearden, S., & Hall, A. R. (2021). Solid-state nanopore analysis of human genomic DNA shows unaltered global 5-hydroxymethylcytosine content associated with early-stage breast cancer. Nanomedicine : nanotechnology, biology, and medicine, 35102407. https://doi.org/10.1016/j.nano.2021.102407
Zahid, Osama K, et al. "Solid-state nanopore analysis of human genomic DNA shows unaltered global 5-hydroxymethylcytosine content associated with early-stage breast cancer." Nanomedicine : nanotechnology, biology, and medicine vol. 35 (2021): 102407. doi: https://doi.org/10.1016/j.nano.2021.102407
Zahid OK, Rivas F, Wang F, Sethi K, Reiss K, Bearden S, Hall AR. Solid-state nanopore analysis of human genomic DNA shows unaltered global 5-hydroxymethylcytosine content associated with early-stage breast cancer. Nanomedicine. 2021 Jul;35:102407. doi: 10.1016/j.nano.2021.102407. Epub 2021 Apr 24. PMID: 33905828; PMCID: PMC8238847.
Copy Download .nbib Format: NLM
Dynamic mRNA polyplexes benefit from bioreducible cleavage sites for in vitro and in vivo transfer.

Journal of controlled release : official journal of the Controlled Release Society

Krhač Levačić A, Berger S, Müller J, Wegner A, Lächelt U, Dohmen C, Rudolph C, Wagner E.
PMID: 34547258
J Control Release. 2021 Nov 10;339:27-40. doi: 10.1016/j.jconrel.2021.09.016. Epub 2021 Sep 20.

Currently, messenger RNA (mRNA)-based lipid nanoparticle formulations revolutionize the clinical field. Cationic polymer-based complexes (polyplexes) represent an alternative compound class for mRNA delivery. After establishing branched polyethylenimine with a succinylation degree of 10% (succPEI) as highly effective positive mRNA...

Cite
Krhač Levačić A, Berger S, Müller J, et al. Dynamic mRNA polyplexes benefit from bioreducible cleavage sites for in vitro and in vivo transfer. J Control Release. 2021;339:27-40doi: 10.1016/j.jconrel.2021.09.016.
Krhač Levačić, A., Berger, S., Müller, J., Wegner, A., Lächelt, U., Dohmen, C., Rudolph, C., & Wagner, E. (2021). Dynamic mRNA polyplexes benefit from bioreducible cleavage sites for in vitro and in vivo transfer. Journal of controlled release : official journal of the Controlled Release Society, 33927-40. https://doi.org/10.1016/j.jconrel.2021.09.016
Krhač Levačić, Ana, et al. "Dynamic mRNA polyplexes benefit from bioreducible cleavage sites for in vitro and in vivo transfer." Journal of controlled release : official journal of the Controlled Release Society vol. 339 (2021): 27-40. doi: https://doi.org/10.1016/j.jconrel.2021.09.016
Krhač Levačić A, Berger S, Müller J, Wegner A, Lächelt U, Dohmen C, Rudolph C, Wagner E. Dynamic mRNA polyplexes benefit from bioreducible cleavage sites for in vitro and in vivo transfer. J Control Release. 2021 Nov 10;339:27-40. doi: 10.1016/j.jconrel.2021.09.016. Epub 2021 Sep 20. PMID: 34547258.
Copy Download .nbib Format: NLM
Understanding Modifiable and Unmodifiable Older Adult Fall Risk Factors to Create Effective Prevention Strategies.

American journal of lifestyle medicine

Bergen G, Stevens MR, Kakara R, Burns ER.
PMID: 34916876
Am J Lifestyle Med. 2019 Oct 21;15(6):580-589. doi: 10.1177/1559827619880529. eCollection 2021.

Each year, more than 1 in 4 older adults in the United States report a fall and 1 in 10 a fall injury. Using nationally representative data from the 2016 US Behavioral Risk Factor Surveillance System, we evaluated demographic,...

Cite
Bergen G, Stevens MR, Kakara R, et al. Understanding Modifiable and Unmodifiable Older Adult Fall Risk Factors to Create Effective Prevention Strategies. Am J Lifestyle Med. 2019;15(6):580-589doi: 10.1177/1559827619880529.
Bergen, G., Stevens, M. R., Kakara, R., & Burns, E. R. (2021). Understanding Modifiable and Unmodifiable Older Adult Fall Risk Factors to Create Effective Prevention Strategies. American journal of lifestyle medicine, 15(6), 580-589. https://doi.org/10.1177/1559827619880529
Bergen, Gwen, et al. "Understanding Modifiable and Unmodifiable Older Adult Fall Risk Factors to Create Effective Prevention Strategies." American journal of lifestyle medicine vol. 15,6 (2021): 580-589. doi: https://doi.org/10.1177/1559827619880529
Bergen G, Stevens MR, Kakara R, Burns ER. Understanding Modifiable and Unmodifiable Older Adult Fall Risk Factors to Create Effective Prevention Strategies. Am J Lifestyle Med. 2019 Oct 21;15(6):580-589. doi: 10.1177/1559827619880529. eCollection 2021. PMID: 34916876; PMCID: PMC8669903.
Copy Download .nbib Format: NLM
S95021, a novel selective and pan-neutralizing anti interferon alpha (IFN-α) monoclonal antibody as a candidate treatment for selected autoimmune rheumatic diseases.

Journal of translational autoimmunity

Duguet F, Ortega-Ferreira C, Fould B, Darville H, Berger S, Chomel A, Leclerc G, Kisand K, Haljasmägi L, Hayday AC, Desvaux E, Nony E, Moingeon P, De Ceuninck F.
PMID: 33748735
J Transl Autoimmun. 2021 Mar 01;4:100093. doi: 10.1016/j.jtauto.2021.100093. eCollection 2021.

Increased interferon-α (IFN-α) production is a critical component in the pathophysiology of systemic lupus erythematosus (SLE) and other rheumatic autoimmune diseases. Herein, we report the characterization of S95021, a fully human IgG1 anti-IFN-α monoclonal antibody (mAb) as a novel...

Cite
Duguet F, Ortega-Ferreira C, Fould B, et al. S95021, a novel selective and pan-neutralizing anti interferon alpha (IFN-α) monoclonal antibody as a candidate treatment for selected autoimmune rheumatic diseases. J Transl Autoimmun. 2021;4:100093doi: 10.1016/j.jtauto.2021.100093.
Duguet, F., Ortega-Ferreira, C., Fould, B., Darville, H., Berger, S., Chomel, A., Leclerc, G., Kisand, K., Haljasmägi, L., Hayday, A. C., Desvaux, E., Nony, E., Moingeon, P., & De Ceuninck, F. (2021). S95021, a novel selective and pan-neutralizing anti interferon alpha (IFN-α) monoclonal antibody as a candidate treatment for selected autoimmune rheumatic diseases. Journal of translational autoimmunity, 4100093. https://doi.org/10.1016/j.jtauto.2021.100093
Duguet, Fanny, et al. "S95021, a novel selective and pan-neutralizing anti interferon alpha (IFN-α) monoclonal antibody as a candidate treatment for selected autoimmune rheumatic diseases." Journal of translational autoimmunity vol. 4 (2021): 100093. doi: https://doi.org/10.1016/j.jtauto.2021.100093
Duguet F, Ortega-Ferreira C, Fould B, Darville H, Berger S, Chomel A, Leclerc G, Kisand K, Haljasmägi L, Hayday AC, Desvaux E, Nony E, Moingeon P, De Ceuninck F. S95021, a novel selective and pan-neutralizing anti interferon alpha (IFN-α) monoclonal antibody as a candidate treatment for selected autoimmune rheumatic diseases. J Transl Autoimmun. 2021 Mar 01;4:100093. doi: 10.1016/j.jtauto.2021.100093. eCollection 2021. PMID: 33748735; PMCID: PMC7972961.
Copy Download .nbib Format: NLM
Showing 349 to 352 of 352 entries